• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Antidepressants for Suicidal Ideation in Depressed Patients?
RESEARCH UPDATE

Antidepressants for Suicidal Ideation in Depressed Patients?

July 1, 2022
James Black, MD
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue

James Black, MD. Dr. Black has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Dunlop BW et al, Psychol Med 2019;49(11):1869–1878

TYPE OF STUDY: Post-hoc analysis of a randomized controlled trial

Antidepressants and cognitive behavior therapy (CBT) appear roughly equivalent for treating depression (Weitz ES et al, JAMA Psychiatry 2015;72(11):1102–1109), but might they differ in their efficacy for individual symptoms of depression (eg, insomnia, decreased appetite, and suicidal ideation)?

To explore this question, researchers randomized 315 depressed adults to either 12 weeks of CBT or medication treatment (escitalopram or duloxetine). They used the Montgomery-Åsberg Depression Rating Scale (MADRS) to identify residual (ie, persisting) symptoms in the 250 subjects who completed the study (n = 110 with severe depression, n = 140 with moderate depression). Subjects were categorized as responders if their MADRS score dropped by more than half during treatment. Residual symptoms from the CBT and medication groups were compared for each MADRS item, and residual symptoms of responders were compared to nonresponders.

About two-thirds of the subjects were treatment responders (59% in the CBT group and 69% in the medication group), and residual symptoms, as measured by MADRS items, were comparable among CBT and medication groups. However, among the nonresponders, CBT subjects’ mean score on suicidal ideation rose by 15%, while it dropped by 70% in the medication group—ie, even when patients failed to respond to antidepressants, their suicidal thoughts diminished.

CARLAT TAKE

Although both CBT and medications were effective for depression in this study, among treatment nonresponders, antidepressants significantly reduced suicidal ideation. CBT had the opposite effect, with suicidal ideation increasing among nonresponders.

KEYWORDS antidepressant cognitive behavioral therapy depression mood disorders suicidality
James Black, MD

Can Pimavanserin Treat Psychosis in Patients With Dementia?

More from this author
www.thecarlatreport.com
Issue Date: July 1, 2022
SUBSCRIBE NOW
Table Of Contents
Psychiatric Medication–Induced Hyperprolactinemia
Minimizing the Use of Seclusion and Restraints
Treating Common Medical Conditions in Patients With Chronic Mental Illnesses
EmPATH Units: An Innovative Approach to Mental Health Crises
Lithium Exposure In Utero—How Bad Is It Really?
Antidepressants for Suicidal Ideation in Depressed Patients?
CME Post-Test - Minimizing Use of Restraints, CHPR, July/August/September 2022
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.